Ulcerative Colitis Therapeutics PipelineReview H1 2015 Market Research Report

DALLAS, February 4, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Ulcerative Colitis - Pipeline Review, H1 2015" to its store. This report provides an overview of the Ulcerative Colitis's therapeutic pipeline and key players involved in the therapeutic development for Botulism and special features on late-stage and discontinued projects.

The report "Ulcerative Colitis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for ulcerative colitis. Ulcerative colitis may sometimes lead to life-threatening complications as it is the result of an abnormal response of body's immune system. Ulcerative colitis usually affects people between 15 to 30 years old. The actual cause of ulcerative colitis remains unidentified but a viral or bacterial infection of the colon may start the abandoned inflammation related with ulcerative colitis.

A variety of diagnostic procedures and lab tests are used to differentiate ulcerative colitis from other situations. For example, colonoscopy with biopsy is often used in UC diagnosis. According to the Crohn's & Colitis Foundation of America, Ulcerative colitis may affect as many as 700,000 Americans. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report also reviews key players involved in the therapeutic development for ulcerative colitis and special features on late-stage and discontinued projects. Companies discussed in this ulcerative colitis pipeline review H1 2015 report include Ajinomoto Pharmaceuticals Co., Ltd., AlphaMab Co., Ltd, Altheus Therapeutics, Inc., Am-Pharma B.V., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Athersys, Inc., Atlantic Healthcare plc, Avaxia Biologics, Inc., Biocon Limited, BioLineRx, Ltd., Bristol-Myers Squibb Company, Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., ChironWells GmbH, Cosmo Pharmaceuticals S.p.A, Dr. Falk Pharma GmbH, Drais Pharmaceuticals, Inc., Effimune SAS, Emergent BioSolutions Inc., Enceladus Pharmaceuticals BV, Epirus Biopharmaceuticals, Inc., Euroscreen S.A., Farmacija d.o.o. Tuzla, Flexion Therapeutics, Inc., Galapagos NV, Genentech, Inc., Genfit SA, Genor BioPharma Co., Ltd., Gilead Sciences, Inc., GT Biologics Limited, GW Pharmaceuticals plc, iCo Therapeutics Inc., InDex Pharmaceuticals AB, INOXIA Lifesciences GmbH, Invion Limited, Johnson & Johnson, Kaken Pharmaceutical Co., Ltd., LIPID THERAPEUTICS GmbH, LTT Bio-Pharma Co., Ltd., Mabion SA, Medestea Research & Production S.p.A., Morphotek, Inc., Nogra Pharma Limited, Oncobiologics, Inc., Pfizer Inc., Pluristem Therapeutics Inc., ProtAb Ltd, Qu Biologics Inc., Receptos, Inc., Sandoz Inc., Sanofi, Sigmoid Pharma Limited, Stelic Institute & Co., sterna biologicals Gmbh & Co KG, Synergy Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TiGenix NV, Tillotts Pharma AG, Trino Therapeutics Ltd, Vascular Biogenics Ltd., Ventria Bioscience, Zyngenia, Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269509 . (This is a premium report priced at US$2000 for a single user License.)

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.This report also review the Botulism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Provide a detailed assessment of monotherapy and combination therapy pipeline projects and also provide strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies.

Drugs profiled discuss in this report include AB-0045, abrilumab, ABS-11, adalimumab biosimilar, AJM-300, alicaforsen sodium, Anatabine, apremilast, ASP-3291, AVX-470, AW/EPO-002, AW/EPO-003, AW/EPOPD-01, AW/EPOPD-02, bertilimumab, BL-7040, BLI-1006, brilacidin, budesonide, budesonide ER, budesonide ER, CCX-507, CNDO-201, Cx-602, cyclosporine CR, DIMS-0150, eldelumab, enalaprilat, ES-210, ESN-282, etrolizumab, FX-003, GED-0507, GFT-505, GLPG-0974, GLPG-1205, GS-5745, GWP-42003, hyaluronate sodium, IAC VITA, infliximab, INV-103, INV-88, KAG-308, KANAb-071, Leukothera, Low Molecular Weight Heparin, LT-0011, LT-02, MD-707, mesalamine, mesalamine CR, mesalamine ER, MultiStem, naltrexone, Nanocort, peficitinib, PF-00547659, PH-44, PH-46A, PH-5, Prozumab, QBECO, Rosburix, RPC-1063, SAR-252067, SB-012, SD-010, Small Molecule for Ulcerative Colitis and Inflammation, SP-333, STNM-01, TAK-114, tofacitinib, TP-10, VB-201, VEDA-1209, vedolizumab, VEN-120.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to Buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Gastrointestinal therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/gastrointestinal-therapeutics .

About Us: 

RnRMarketResearch.com is a database of selected syndicated market reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Contact:  
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

SOURCE RnR Market Research